Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aritinercept in Generalized Myasthenia Gravis
NCT07596901Phase 2Recruiting
- Sponsor
- Aurinia
- Start
- Apr 2026
- Primary completion
- Mar 2029
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of aritinercept in myasthenia gravis (MG), sponsored by Aurinia. Started Apr 2026; status: recruiting.
02
Drugs
aritinercept
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT07596901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07596901.